Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia

Health Policy

Volumn 87, Issue 2, 2008, Pages 133-145

  Morgan, Steve ^a   McMahon, Meghan ^b   Greyson, Devon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Australia; Health policy; Industrial policy; Pharmaceutical policy; Pharmaceuticals

Indexed keywords

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMIC DEVELOPMENT; ELECTRONIC DATA INTERCHANGE; ENVIRONMENTAL FACTOR; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; INVESTMENT; MEDICAL LITERATURE; PHARMACY; PROFIT; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW;

AUSTRALIA; DRUG INDUSTRY; DRUGS, ESSENTIAL; ECONOMICS, PHARMACEUTICAL; HEALTH CARE SECTOR; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; ORGANIZATIONAL CASE STUDIES; ORGANIZATIONAL OBJECTIVES; RESEARCH SUPPORT AS TOPIC;

EID: 45549091177     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.01.003     Document Type: Review

References (49)

1. Vandergrift M., and Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 41 (1997) 241-260
2. Maynard A., and Cookson R. Money or your life? The health-wealth trade-off in pharmaceutical regulation. Journal of Health Services and Policy Research 6 (2001) 186-189
3. In: Mossialos E., Mrazek M.F., and Walley T (Eds). Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (2004), Open University Press
4. Morgan S., McMahon M., Mitton C.R., et al. Centralized drug review processes in Australia, Canada, New Zealand and the United Kingdom. Health Affairs 25 (2006) 337-347
5. Jacobzone S. Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals. Occasional Papers, No. 40. OECD Directorate for Education, Employment, Labour and Social Affairs. http://www.olis.oecd.org/OLIS/2000DOC.NSF/LINKTO/DEELSA-ELSA-WD(2000)1; 2000.
6. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme: An OFT Market Study. London: OFT. http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf; 2007.
7. Lofgren H., and de Boer R. Pharmaceuticals in Australia: developments in regulation and governance. Social Science & Medicine 58 (2004) 2397-2407
8. Department of Health and Ageing. National Medicines Policy 2000. http://www.health.gov.au/internet/wcms/Publishing.nsf/Content/nmp-pdf-nmp2000-cnt.htm/AUD$FILE/nmp2000.pdf; 2000.
9. Australian Pharmaceutical Advisory Council. Strategic Plan: 2002-2005. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-pdf-apacplan-cnt.htm/AUD$FILE/apacplan.pdf; 2002.
10. Department of Health and Ageing. About the PBS. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-general-aboutus.htm-copy2; January 2007.
11. Lopert R. Patients, physicians and pharma. Workshop, Israel Institute for Health Policy and Health Services Research. Haifa, April (2006)
12. Australia Institute for Health and Welfare. Health Expenditure Australia 2004-2005. AIHW Cat. no. HWE 35. http://www.aihw.gov.au/publications/index.cfm/title/10350; September 2006.
13. Data and Modeling Section, Pharmaceutical Policy and Analysis Branch. Expenditure and Prescriptions 12 Months to 30 June 2006. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/Pharmaceutical+Benefits+Scheme+%28PBS%29-3; 2006.
14. Medicare Australia. PBS Safety Net. Page updated 12 February 2007. http://www.medicareaustralia.gov.au/yourhealth/our_services/pbs_safety_net.shtml#what_to_do; 2007.
15. Department of Health and Ageing. Questions and Answers on New Pricing and Listing Arrangements for Generic Medicines on the Pharmaceutical Benefits Scheme. Page Updated 22 April 2005. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-pricereductions/AUD$FILE/qa22april.pdf; 2005.
16. Anell A. Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees. European Journal of Health Economics 5 (2004) 28-35
17. Graf von der Schulenburg J.M., and Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC: Health Economics in Prevention and Care 1 (2000) 2-8
18. Wonder M.J., Neville A.M., and Parsons R. Are Australians able to access new medicines on the Pharmaceutical Benefits Scheme in a more or less timely manner? An analysis of Pharmaceutical Benefits Advisory Committee recommendations, 1999-2003. Value in Health 9 (2006) 205-212
19. Pharmaceutical Benefits Pricing Authority. Policies, Procedures and Methods Used in the Pricing of Pharmaceutical Products. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/A7B2821D76A9A622CA256F180046E10A/AUD$File/pbpa%20manual%20aug06.pdf; May 2006.
20. Pharmaceutical Research and Manufacturers of America (PhRMA) Special 301 Submission 2007. http://members.phrma.org/international/PhRMA_Special_301_Submission_2007.pdf; 2007.
21. Department of Health and Ageing. November 2006 PBAC Outcomes: Results of Independent Review. http://www.health.gov.au/internet/wcms/publishing.nsf/content/pbacrec-nov06-results; 2006.
22. Hon Tony Abbott MP, Minister for Health and Ageing. AUSFTA and the PBS: Statement on the Implementation of Australia's AUSFTA Commitments, February 2005. Commonwealth of Australia. http://www.independentreviewpbs.gov.au/internet/independentreviewpbs/publishing.nsf/Content/1BF60EEB66DB9E67CA2571B500837199/AUD$File/Statement_on_the_Implementation_of_Australias_AUSFTA_Commitments-February_2005.pdf; 2005.
23. Faunce T., Doran E., Henry D., et al. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Globalization and Health 1 (2005) 1-10
24. Harvey K. Patents, pills and politics: the Australia-United State Free Trade Agreement and the pharmaceutical benefits scheme. Australian Health Review 28 (2004) 218-226
25. Harvey K.J., Faunce T.A., Lokuge B., and Drahos P. Will the Australia-United States Free Trade Agreement undermine the pharmaceutical benefits scheme?. Medical Journal of Australia 181 (2004) 256-259
26. Pharmaceutical Benefits Pricing Authority. Policies, Procedures and Methods Used in the Pricing of Pharmaceutical Products; http://www.health.gov.au/internet/wcms/publishing.nsf/Content/A7B2821D76A9A622CA256F180046E10A/AUD$File/pbpa%20manual%20aug06.pdf; 2006.
27. Fortune 500. Top Industries 2007; 30 April 2007 http://money.cnn.com/magazines/fortune/fortune500/2007/performers/industries/return_on_revenues/index.html; 2007.
28. Organisation for Economic Cooperation and Development. Biotechnology, Innovation and Health. Directorate for Science, Technology and Industry, Paris; 2004.
29. Economist Intelligence Unit. Benchmarking Study of the Characteristics of the Australian and International Pharmaceuticals Industries. Final Report; 2005.
30. Department of Industry, Tourism and Resources. AusIndustry Fact Sheet. Last reviewed 18 May 2007. http://www.industry.gov.au/content/itrinternet/cmscontent.cfm?objectid=D635070F-62F0-4C71-8A97FB8EACD82F60&indexPages=/content/itrinternet/cmsindexpage.cfm?objectid=48A5DFEA-20E0-68D8-EDB550B8BD2CB714&indexType=crossindustry; 2007.
31. Productivity Commission. Public Support for Science and Innovation. Productivity Commission Research Report. Commonwealth of Australia; 2007.
32. AusIndustry. Pharmaceuticals Partnerships Program (P3) Fact Sheet. http://www.ausindustry.gov.au/content/content.cfm?ObjectID=229AEF11-7DC5-4DFA-B95F72C194FCA90D.
33. Industry Commission. The Pharmaceutical Industry. Industry Commission Inquiry Report. Report No. 51. http://www.pc.gov.au/ic/inquiry/51drugs/finalreport/51drugsv1.pdf; 1996.
34. Hill J, Kirchner A, Holmes A from the Pharmaceuticals Industry Action Agenda Team. Pharmaceuticals Industry Action Agenda: Discussion Paper. Pharmaceuticals Section, Department of Industry, Tourism and Resources. http://www.industry.gov.au/assets/documents/itrinternet/PIAAdiscussionpapersep0120050525143934.pdf; 2001.
35. Productivity Commission. Evaluation of the Pharmaceutical Industry Investment Program. Research Report, AusInfo, Canberra. http://www.pc.gov.au/study/piip/finalreport/piip.pdf; 2003.
36. Pharmaceuticals Industry Action Agenda. Pharmaceuticals Industry Action Agenda: Local Priority, Global Partner: Executive Summary. http://www.industry.gov.au/assets/documents/itrinternet/PIAAreport2002execsummary20050525121232.pdf; 2002.
37. Duckett S.J. Drug policy down under: Australia's pharmaceutical benefits scheme. Health Care Financing Review 25 (2004) 55-67
38. Organisation for Economic Cooperation and Development. Tax Incentives for Research and Development: Trends and Issues. Directorate for Science, Technology and Industry, Paris. http://www.oecd.org/dataoecd/12/27/2498389.pdf; 2003.
39. Productivity Commission. International Pharmaceutical Price Differences, Research Report. AusInfo, Canberra. http://www.pc.gov.au/study/pbsprices/finalreport/pbsprices.pdf; 2001.
40. Roughead E.E., Lopert R., and Sansom L.N. Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the US. Value in Health 10 6 (2007) 514-520
41. Loff B., and Cordner S. Australian government loosens its grip on the pharmaceutical industry. Lancet 357 (2001) 453
42. Doran E., and Henry D. Pharmaceutical benefits scheme policy: confused and tough on patients (Editorial). Internal Medicine Journal 36 (2006) 211-213
43. Faunce T. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?. The Medical Journal of Australia 187 4 (2007) 240-242
44. Department of Health and Ageing. Strengthening your PBS: Preparing for the Future. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/A2F23E7630B8F9F3CA257227007F1EC7/AUD$File/strengthening-your-PBS161106.pdf; 2007.
45. Hon Tony Abbott MP, Minister for Health and Ageing. Transcript: Press conference-PBS Reform, Thursday, November 16, 2006. http://www.guild.org.au/public/currentissues/Abbott-061116-PressConf-PBSreform.pdf; 2006.
46. Pharmaceutical Benefits Pricing Authority. Annual Report for the Year Ended 30 June 2006. Commonwealth of Australia. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/D54934A7E75638F6CA2572170082946F/AUD$File/pbpa%20annual%20report%202006.pdf; 2006.
47. Anis A.H. Substitution laws, insurance coverage, and generic drug use. Medical Care 32 (1994) 240-256
48. Department of Health and Ageing. Fact Sheet: Pharmaceutical Benefits Scheme Reform. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/24693658DD49E286CA2572750081DB74/AUD$File/PBS%20Reform%202Feb07.pdf; February 2007-09-05.
49. Stafford A. Pharmacy scheme shake up slash cost of medicines: End to backdoor drug discounts. Age, General News, A3. 17 November 2006. http://www.guild.org.au/public/currentissues/20061117PBS%20Reform%20Stories.pdf; 2006.